Elsevier

Human Pathology

Volume 38, Issue 8, August 2007, Pages 1232-1238
Human Pathology

Original contribution
The invasive front in endometrial carcinoma: higher proliferation and associated derailment of cell cycle regulators

https://doi.org/10.1016/j.humpath.2007.01.008Get rights and content

Summary

The aim of the study was to explore whether expression of proliferation and hypoxia-related proteins differs in the central parts and the invasive front in endometrial carcinomas. Proliferation-associated proteins Ki67 and cyclin A; cell cycle regulators p16, p21, p53, cyclin D1, cyclin E, and cdk2; and hypoxia-inducible factor 1α and its downstream factors glucose transporter 1, carbonic anhydrase IX, and vascular endothelial growth factor were immunohistochemically stained in paraffin-embedded specimens from endometrioid (n = 33), mucinous (n = 1), and serous (n = 5) endometrial carcinomas. The percentages of positive cells at the invasive front and central tumor parts were scored and compared. Ki67 (P < .001), cyclin E (P = .018), p16 (P = .003), and cdk2 (.001) were expressed higher at the invasive front than centrally (Wilcoxon signed ranks test). Higher expression of these antigens at the invasive front was seen in 31 of 38 cases for Ki67, in 16 of 39 cases for cyclin E, in 15 of 39 cases for cdk2, and in 11 of 39 cases for p16. The other cell cycle proteins and the hypoxia-related factors did not show significant differences in expression between the central parts and the invasive front. Endometrial carcinomas clearly show an invasive front that is characterized by higher proliferation and progressive derailment of the cell cycle regulators cyclin E, p16, and cdk2, but not by an increased hypoxic response.

Introduction

For a tumor to become malignant, several phenomena are important, of which the following are perhaps the most essential: proliferation outweighing cell death, cellular dedifferentiation, and ability to invade the environment and to metastasize. This ability of cancer cells to invade the surrounding stroma and vessels is linked to patient prognosis because of associations with advanced local invasive tumor growth and distant spread. Tumor invasion is a complex process that involves cell attachment, proteolysis of matrix components, migration of cells through the disrupted matrix, proliferation, and angiogenesis [1].

As to the latter 2 phenomena, aberrations in the regulation of cell cycle control lead to uncontrolled proliferation; and angiogenesis is to a large extent regulated by the hypoxia response. The cell cycle, which is progressively deregulated during carcinogenesis, is controlled by cyclins such as cyclins A, D1, and E; cyclin-dependent kinases (CDKs) such as cdk2 and cdk4; cyclin-dependent kinase inhibitors (CKIs) such as p16, p21, and p27; and tumor suppressor gene products such as p53. Overexpression of cell cycle stimulating factors such as the CDKs and cyclins and downregulation of inhibiting factors such as CKIs are frequently found in tumors, including endometrial carcinoma. It is described that they are correlated with a more malignant subtype, a higher proliferation rate, recurrence, and a worse survival in different tumors [2], [3], [4], [5], [6], [7], [8], [9].

Hypoxia-inducible factor 1α (HIF-1α) is the key regulator of the hypoxia response [10] and has been implicated in carcinogenesis and cancer progression in many different epithelia including the female epithelia of the endometrium [11] and breast [12], [13]. HIF-1α is a transcription factor upregulating many genes [14] that are involved in adaptation to low glucose levels such as the glucose transporter Glut-1, carbonic anhydrase IX (CAIX) that regulates pH [15], and vascular endothelial growth factor (VEGF) that is one of the most potent inducers of angiogenesis [16].

Endometrial cancer is the most common malignant tumor of the female genital tract. Estimated incidence of cancer in the uterine corpus in the United States was 40 880 for 2006 (6% of all cancers), with an estimated probability of developing uterine cancer of 1 in 38 [17]. Endometrial cancer derives from the endometrial epithelial lining of the uterine corpus. During cancer progression, some endometrial cancers grow as polyps; but most invade downward into the myometrium. Conceptually, the deepest parts of the tumors invading the myometrium must be the most active and aggressive ones, showing highest proliferation, invasive behavior, and angiogenesis. Such an “invasive front” has been described in, for example, female breast cancer, where the highest proliferation is known to be in the periphery of the tumor [18], but has not been evaluated yet in endometrial cancer. While analyzing expression of cell cycle–related proteins during endometrial carcinogenesis in a previous study (N. H., unpublished data), we noticed a tendency for some proteins to be preferentially expressed at the invasive front of endometrial carcinomas. The aim of the present study was to perform a comprehensive analysis of the topographical expression of cell cycle regulators and proteins related to the hypoxia response, comparing central tumor parts with the invasive front.

Section snippets

Patients and tissues

Paraffin-embedded specimens from endometrioid endometrial carcinoma (n = 33), mucinous carcinoma (n = 1), and serous endometrial carcinoma (n = 5) with tumor and myometrium on one slide were selected from the archives of the Department of Pathology of the University Medical Center, Utrecht, the Netherlands. These tissues were derived from patients operated on between 1992 and 2004. None of the patients received preoperative radio- or chemotherapy.

Hematoxylin and eosin–stained sections were

Cell cycle proteins

Table 2 gives an overview of the expression of the cell cycle–related proteins in the central parts of the tumor and at the invasive front. For MIB-1 (P < .001), cyclin E (P = .018), cdk2 (.001), and p16 (P = .003), differences between the percentages of positive cells in these areas of the tumor were statistically significantly different (Wilcoxon signed ranks test) (further illustrated in Fig. 1A-D). p53 showed a borderline-significant difference between the invasive front and the center

Discussion

The purpose of this study was to objectively investigate differences in topography of proliferation (MIB-1), aberrant expression of cell cycle regulators and HIF-1α with 3 of its downstream factors, Glut-1, CAIX, and VEGF. This is the first study considering this subject in endometrial carcinoma. The concept of an invasive front has been proposed in other cancers, but differences in definitions and methods in these studies make comparisons difficult [20], [21], [22], [23], [24], [25], [26], [27]

Acknowledgments

We thank D. van Wichen from the Department of Pathology, University Medical Center Utrecht, for his support in creating the figures.

References (40)

  • C. Bergstrom et al.

    Factors influencing the estimates of proliferative labelling indices in rectal cancer

    Radiother Oncol

    (1998)
  • B. Tringler et al.

    Evaluation of p16INK4a and pRb expression in cervical squamous and glandular neoplasia

    Hum Pathol

    (2004)
  • S. Aznavoorian et al.

    Molecular aspects of tumor cell invasion and metastasis

    Cancer

    (1993)
  • N. Kato et al.

    Immunohistochemical expression of cyclin E in endometrial adenocarcinoma (endometrioid type) and its clinicopathological significance

    J Cancer Res Clin Oncol

    (2003)
  • K. Milde-Langosch et al.

    Role of cell-cycle regulatory proteins in gynecological cancer

    J Cell Physiol

    (2003)
  • K. Ito et al.

    Correlations between p21 expression and clinicopathological findings, p53 gene and protein alterations, and survival in patients with endometrial carcinoma

    J Pathol

    (1997)
  • H.B. Salvesen et al.

    Prognostic significance of angiogenesis and Ki-67, p53, and p21 expression: a population-based endometrial carcinoma study

    J Clin Oncol

    (1999)
  • D.G. Rosen et al.

    Cyclin E expression is correlated with tumor progression and predicts a poor prognosis in patients with ovarian carcinoma

    Cancer

    (2006)
  • S. Singhal et al.

    Prognostic implications of cell cycle, apoptosis, and angiogenesis biomarkers in non–small cell lung cancer: a review

    Clin Cancer Res

    (2005)
  • E. Sivridis et al.

    Association of hypoxia-inducible factors 1 alpha and 2 alpha with activated angiogenic pathways and prognosis in patients with endometrial carcinoma

    Cancer

    (2002)
  • Cited by (44)

    • Diagnosis of endometrium hyperplasia and screening of endometrial intraepithelial neoplasia in histopathological images using a global-to-local multi-scale convolutional neural network

      2022, Computer Methods and Programs in Biomedicine
      Citation Excerpt :

      Furthermore, molecular classification based on The Cancer Genome ATLAS (TCGA) has been used to stratify EC as four subtypes with distinct clinical course and progression-free survival [48,49]. In particular, high expression of tumor protein p53 [50,51] and β-catenin [52,53], and low expression of phosphatase and tensin homologue (PTEN) [54,55], AT-rich interactive domain-containing protein 1 A (ARID1A) [56,57], DNA mismatch repair (MMR) (including MLH1, MSH2 and MSH6) [58,59] and B-cell lymphoma 2 (Bcl-2) [6,60] may predict the progression from NE/HwA, though EIN, to EC. Despite sometimes encountering inconsistent or even conflicting results, future integration of these molecular biomarkers into the DL-based histological analysis may benefit the overall diagnostic performance.

    • Hypoxia induces core-to-edge transition of progressive tumoral cells: A critical review on differential yet corroborative roles for HIF-1α and HIF-2α

      2020, Life Sciences
      Citation Excerpt :

      For high-stage tumors, suppression of HIF-2α would exert more durable effects, as there is an evidence for pancreatic cancer that exposure of tumoral cells with chronic hypoxia can cause HIF-2α (not HIF-1α) inducible effects on chronic metabolic changes in the cells [42] (Fig. 1). This is in conflicting with the work presented by Horree and colleagues who showed a balance in the expression of HIF-1α and HIF-2α (no precedence in the transcription between the two factors) at the core and invasive areas of endometrial cancer [60], as well as with the results reported by Scarpino and coworkers who noticed high presence of HIF-1α at the invasive front of thyroid tumor [61]. For both studies no stage of tumor was determined to see whether the trait of expressions for HIFs is influenced from tumor grade, and that a limitation for the second report is that no assessment for HIF-2α was performed to compare the results with the rate for HIF-1α at the invasive edge of tumor.

    • Endometrial cancer biomarkers

      2022, Endometrial Cancer: Current Epidemiology, Detection and Management (Second Edition)
    View all citing articles on Scopus
    View full text